MedTrace Logo

Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin

NCT00003558 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2013-08-07

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective for cancer of unknown primary origin.

PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of combination chemotherapy in treating patients with cancer of unknown primary origin.

Conditions

  • Carcinoma of Unknown Primary

Interventions

DRUG

carboplatin

DRUG

etoposide

DRUG

fluorouracil

DRUG

leucovorin calcium

DRUG

paclitaxel

Sponsors & Collaborators

  • Academisch Ziekenhuis Maastricht

    lead OTHER

Principal Investigators

  • R. L. Jansen, MD, PhD · Academisch Ziekenhuis Maastricht

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-08-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003558 on ClinicalTrials.gov